Search PubMed⌕ Search

Biomedical subjects

J Takeuchi

Publications and source records attributed to J Takeuchi.

472 records · Page 27Linked to original sources

Ultrasonography and computed tomography in adenomyomatosis of the gallbladder.

Ultrasonography and computed tomography were performed in 4 patients with adenomyomatosis of the gallbladder of segmental or diffuse type. Cholecystectomy was performed in all cases, and the diagnosis of adenomyomatosis was confirmed histopathologically. Ultrasonography revealed diffuse or segmental thickening of the gallbladder wall with small intramural diverticula. Small stones were also found. The characteristic findings of adenomyomatosis at computed tomography were soft tissue density masses in the gallbladder fossa, associated with a well-delineated, distinct tumor-free space between the mass and the liver, and with small intramural diverticula and calcified stones within the mass. Ultrasonography and computed tomography demonstrate a characteristic appearance of adenomyomatosis.

Adolescent↗

Durable molecular complete remission induced by low-dose imatinib plus low-dose interferon alpha in a patient with chronic myelogenous leukaemia.

A 50-year-old male was diagnosed with chronic myelogenous leukaemia (CML) in chronic phase in March 2000. He was treated initially with hydroxyurea, administered orally. This was changed to interferon alpha (IFN) 5 million units (5 MIU) subcutaneously daily in May 2000; complete cytogenetic response was achieved 11 months later. IFN dosage was reduced to 5 MIU, alternate days, in June 2001 and a cytogenetic relapse occurred 3 months later. Since April 2002, he has received IFN 5 MIU three times weekly in combination with imatinib 200 mg/day. The Philadelphia chromosome disappeared from his peripheral blood cells in July 2002 and a complete molecular response was achieved in January 2003. Serial molecular studies between January 2004 and January 2005 showed no detectable major BCR/ABL chimeric transcript. Grade 2 neutropenia and grade 1 non-haematological adverse effects have been observed. This case report suggests the combination of low-dose imatinib and IFN would be tolerable and effective for CML patients in chronic phase.

Antineoplastic Agents↗